Sign In
Buy ASND
$243.91
-7.16 (-2.85%)
At Close: Jul 31, 2026
Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024
08:30am, Wednesday, 28'th Aug 2024
COPENHAGEN, Denmark, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report second quarter 2024 financial results and provide a business update on Tuesday,
Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath
01:35pm, Wednesday, 14'th Aug 2024
The FDA approves Ascendis' (ASND) Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adult patients. Shares rise.
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?
10:02am, Wednesday, 14'th Aug 2024
Ascendis Pharma (ASND) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near t
Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming Up
05:25am, Tuesday, 13'th Aug 2024
Ascendis Pharma's shares are modestly higher after the company announced the FDA approval of Yorvipath for the treatment of hypoparathyroidism. The label is broad and clean, without a black box warnin
Monday, the FDA approved Ascendis Pharma A/S' ASND Yorvipath (palopegteriparatide; developed as TransCon PTH) for hypoparathyroidism in adults.
Ascendis Pharma's stock surges after FDA approval for first and only treatment for rare disease
08:51am, Monday, 12'th Aug 2024
The stock of Ascendis Pharma A/S jumped 11% early Monday, after the biotech said the U.S. Food and Drug Administration has approved its Yorvipath as the first and only treatment for a rare endocrine d
FDA approves Ascendis Pharma's hormone disorder therapy
07:23am, Monday, 12'th Aug 2024
The U.S. Food & Drug Administration has approved Ascendis Pharma's therapy to treat adult patients with a hormone disorder, bringing an end to its years-long efforts to introduce the treatment to the
Weaker USD, Revenue Growth, And TransCon Technology Make Ascendis Pharma A Strong Buy Opportunity
05:52am, Monday, 29'th Jul 2024
ASND's pipeline includes promising candidates for various endocrine disorders and oncology, positioning the company as a leader in innovative medical solutions. FDA-approved Skytrofa for pediatric GHD
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024
04:45pm, Monday, 24'th Jun 2024
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
04:01pm, Tuesday, 04'th Jun 2024
COPENHAGEN, Denmark, June 04, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Goldman Sachs 45th Annual G
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
04:01pm, Monday, 03'rd Jun 2024
- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist
Ascendis to Spotlight Latest Updates for TransCon™ Rare Endocrinology Disease Portfolio at ENDO 2024
08:30am, Thursday, 30'th May 2024
COPENHAGEN, Denmark, May 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will host informational booths, events, and presentations showcasing use of its innovat
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
11:46am, Wednesday, 15'th May 2024
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
FDA extends review of Ascendis Pharma's hormone disorder therapy
02:43pm, Tuesday, 14'th May 2024
The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder, the company said on Tuesday.
- Prescription Drug User Fee Act (PDUFA) goal date extended by three months for further review of submission to August 14, 2024
